Investor Information

  • Global Wellness Summit - Psilocybin - Boston

Psyence Group Invited as First Psychedelic Company to present at the 15th-Annual Global Wellness Summit

2021-11-27T05:48:16+02:00November 26, 2021|Press Releases, Investor Information, Psychedelic News|

Psyence’s Head of Corporate Social Responsibility, Mary-Elizabeth Gifford, will host an in-person keynote conversation with Rick Doblin, PhD, Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS) on the future of Psychedelics and Healing. 

Dr Dingle Spence to speak at two conferences on psychedelics

2021-10-13T13:40:15+02:00October 13, 2021|Press Releases, Investor Information|

Dr. Spence, an oncologist, palliative care specialist, and health justice activist will speak at the EndWell Conference – “The End in Mind – Psychedelic Medicines & Ending Well” taking place virtually on Thursday, October 14, 2021. Dr. Spence is also a featured speaker at the “Fantastic Fungi Global Summit – The Transformational Power of Mushrooms” taking place virtually on Friday, Saturday, and Sunday October 15-17th 2021.

  • Real Psilocybin | Psychedelic Mushrooms

Psyence completes its first official, validated harvest of psychedelic mushrooms

2021-10-04T11:04:42+02:00October 1, 2021|Investor Information, Psychedelic News|

Psyence Group is one step closer to achieving British Standards Institute (BSI) certification , having completed its first official validated harvest of psychedelic mushrooms (psilocybe cubensis) at its federally-licensed facility In Lesotho, Southern Africa. The state-of-the-art facility has been built to GMP standards, is FDA registered and has been operational since January 2021.

  • Pure Psyence | Pure Extract | Psyence

Pure Psyence: A Joint Venture Sealed between Psyence Group and Pure Extracts

2021-09-29T09:22:59+02:00September 28, 2021|Press Releases, Investor Information, Psychedelic News|

Our Joint Venture with Pure Extracts, "Pure Psyence", is an important milestone for Psyence Group. Pure Psyence will develop nature-derived psilocybin extracts, and advanced psilocybin formulations, for the long-term treatment of psychological trauma and its mental health consequences. The JV's combined expertise in formulation development of psychoactive compounds will enable Pure Psyence to produce stable and effective psilocybin medicinal products and work towards making psilocybin more accessible.

Psyence Group announces the commencement of online sales and distribution of “GOODMIND™” products

2021-08-18T11:55:44+02:00August 18, 2021|Press Releases, Investor Information, Psychedelic News|

We are excited that as of today our functional mushroom nutraceutical product, GOODMIND™ is available online. The GOODMIND™ formulas harness the power of adaptogens, these are non-toxic, non-psychoactive fungi, used for centuries in traditional medicine for their stress-relieving benefits. GOODMIND™ is designed to nourish the mind and elevate everyday life by enhancing mental capacity and the body’s ability to adapt to stress.

  • Diary of a psychedelic exec | episode 06 | Psyence

The Diaries of a Psychedelic Exec : Episode 6

2021-07-22T11:50:31+02:00July 22, 2021|Investor Information, Diary Of A Psychedelic Exec|

Hi, I am Neil Maresky, the new CEO of Psyence. I am delighted to be able to make a contribution to the “Diary of a Psychedelic Exec”. In this episode I reflect on the challenges society is facing when it comes to mental health and why I think psychedelics, and Psyence in particular, have an important role to play in addressing these challenges. I feel privileged to have the opportunity to lead an incredible team at Psyence, all of whom are clearly committed to making an impact on society.

  • The Diaries of a Psychedelic Exec : Episode 4

The Diaries of a Psychedelic Exec : Episode 5

2021-07-12T08:35:32+02:00July 12, 2021|Investor Information, Diary Of A Psychedelic Exec|

It was another exciting week at Psyence as we welcomed Dr. Neil Maresky as Chief Executive Officer of Psyence Group. Based in Canada, Neil brings over twenty years of biopharmaceutical experience to Psyence; he was previously at AstraZeneca. I am now the Executive Chairman of Psyence Group and will work closely with Neil on all aspects of the business going forward. I am also delighted to share news of our partnership agreement with Clerkenwell Health; a leading psychedelic Contract Research Organisation based in the United Kingdom.

Go to Top